URL of this page: https://medlineplus.gov/druginfo/natural/332.html

Saccharomyces Boulardii

What is it?

Saccharomyces boulardii is a yeast, which is a type of fungus. Saccharomyces boulardii was previously identified as a unique species of yeast. But now it is believed to be a strain of Saccharomyces cerevisiae (baker's yeast). Saccharomyces boulardii is used as medicine.

Saccharomyces boulardii is most commonly used for treating and preventing diarrhea, including infectious types such as rotaviral diarrhea in children, diarrhea caused by gastrointestinal (GI) take-over (overgrowth) by "bad" bacteria in adults, traveler's diarrhea, and diarrhea associated with tube feedings. It is also used to prevent and treat diarrhea caused by the use of antibiotics.

How effective is it?

Natural Medicines Comprehensive Database rates effectiveness based on scientific evidence according to the following scale: Effective, Likely Effective, Possibly Effective, Possibly Ineffective, Likely Ineffective, Ineffective, and Insufficient Evidence to Rate.

The effectiveness ratings for SACCHAROMYCES BOULARDII are as follows:

Likely effective for...

  • Diarrhea in people taking antibiotics. Research shows that taking Saccharomyces boulardii can prevent diarrhea caused by taking antibiotics.
  • Diarrhea. Research shows that Saccharomyces boulardii can prevent diarrhea in people with feeding tubes. It also helps reduce the length of time that diarrhea persists in infants and children.

Possibly effective for...

  • Acne. Research shows that taking Saccharomyces boulardii by mouth helps improve the appearance of acne.
  • Diarrhea caused by the bacteria Clostridium difficile. Taking Saccharomyces boulardii by mouth helps prevent diarrhea in people infected by Clostridium difficile bacteria. It might work better in children than adults. Taking Saccharomyces boulardii also seems to prevent diarrhea caused by this bacteria from re-occurring in some people. But it doesn't seem to prevent recurrence in people being treated for Clostridium difficile diarrhea for the first time.
  • Helicobacter pylori. Taking Saccharomyces boulardii by mouth along with standard H. pylori treatment helps treat this infection. About 12 people need to be treated with Saccharomyces boulardii for one patient who would otherwise remain infected to be cured. Taking Saccharomyces boulardii also helps prevent side effects such as diarrhea and nausea that occur with standard H. pylori treatment.
  • Diarrhea related to HIV. Taking Saccharomyces boulardii by mouth appears to reduce diarrhea related to HIV.
  • Traveler's diarrhea. Taking Saccharomyces boulardii by mouth appears to prevent traveler's diarrhea.

Possibly ineffective for...

  • Hyperbilirubinemia (high levels of bilirubin in the blood). Giving Saccharomyces boulardii to infants with high levels of bilirubin in the blood doesn't decrease the length of time for which phototherapy is needed.

Insufficient evidence to rate effectiveness for...

  • Amoeba infections (amebiasis). Early research shows that taking Saccharomyces boulardii by mouth along with antibiotics reduces diarrhea and stomach pain in people with amoeba infections.
  • Crohn's disease. Taking Saccharomyces boulardii seems to reduce the number of bowel movements in people with Crohn's disease. Early research also shows that taking Saccharomyces boulardii along with mesalamine can help people with Crohn's disease stay in remission longer. But taking Saccharomyces boulardii alone does not seem to help people with Crohn's disease stay in remission longer.
  • Cystic fibrosis. Early research shows that taking Saccharomyces boulardii by mouth does not reduce yeast infections in the digestive tract of people with cystic fibrosis.
  • Irritable bowel syndrome (IBS). One study shows that taking Saccharomyces boulardii by mouth along with mesalazine does not improve symptoms of IBS better than taking mesalazine alone.
  • Ulcerative colitis. Early research shows that adding Saccharomyces boulardii to standard mesalamine therapy can reduce symptoms in people with mild-to-moderate ulcerative colitis.
  • Canker sores.
  • Fever blisters.
  • High cholesterol.
  • Hives.
  • Lactose intolerance.
  • Lyme disease.
  • Urinary tract infections (UTIs).
  • Yeast infections.
  • Other conditions.
More evidence is needed to rate Saccharomyces boulardii for these uses.

How does it work?

Saccharomyces boulardii is called a "probiotic," a friendly organism that helps to fight off disease-causing organisms in the gut such as bacteria and yeast.

Are there safety concerns?

Saccharomyces boulardii is LIKELY SAFE for most adults when taken by mouth for up to 15 months. It can cause gas in some people. Rarely, it might cause fungal infections that can spread through the bloodstream to the entire body (fungemia).

Special precautions & warnings:

Children. Saccharomyces boulardii is POSSIBLY SAFE for children when taken by mouth appropriately. However, diarrhea in children should be evaluated by a healthcare professional before using Saccharomyces boulardii.

Pregnancy and breast-feeding: There is not enough reliable information about the safety of taking Saccharomyces boulardii if you are pregnant or breast feeding. Stay on the safe side and avoid use.

Weakened immune system: There is some concern that critically ill people, people who have a weakened immune system, and people who are taking medicines that alter the immune system might have an increased risk for developing a yeast infection that spreads to the bloodstream and the rest of the body (fungemia) if they take Saccharomyces boulardii. Although Saccharomyces generally doesn't cause disease, there have been numerous cases of fungemia following its use, primarily in people with a weakened immune system.

Yeast allergy: People with yeast allergy can be allergic to products containing Saccharomyces boulardii, and are best advised to avoid these products.

Are there interactions with medications?

Be watchful with this combination.
Medications for fungal infections (Antifungals)
Saccharomyces boulardii is a fungus. Medications for fungal infections help reduce fungus in and on the body. Taking Saccharomyces boulardii with medications for fungal infections can reduce the effectiveness of Saccharomyces boulardii.
Some medications for fungal infection include fluconazole (Diflucan), caspofungin (Cancidas), itraconazole (Sporanox) amphotericin (Ambisome), and others.

Are there interactions with herbs and supplements?

There are no known interactions with herbs and supplements.

Are there interactions with foods?

There are no known interactions with foods.

What dose is used?

The following doses have been studied in scientific research:


  • For diarrhea in people taking antibiotics: 250-500 mg of Saccharomyces boulardii two to four times a day for up to 2 weeks is most commonly used. In most cases, daily doses do not exceed 1000 mg daily.
  • For diarrhea caused by Clostridium difficile: 1 gram of Saccharomyces boulardii daily for 4 weeks along with antibiotic treatment.
  • For diarrhea caused by Helicobacter pylori: 500-1000 mg of Saccharomyces boulardii for 1-4 weeks is most commonly used.
  • For diarrhea associated with HIV: 3 grams of Saccharomyces boulardii daily.
  • For traveler's diarrhea: 250-1000 mg of Saccharomyces boulardii daily for 1 month.

  • For diarrhea in people taking antibiotics: 250 mg of Saccharomyces boulardii once or twice daily for the duration of antibiotics has been used.
  • For diarrhea caused by Clostridium difficile: 500 mg of Saccharomyces boulardii daily has been used.
  • For general diarrhea: 250-750 mg of Saccharomyces boulardii daily for up to 5 days is most commonly used.

Other names

Brewer's Yeast (Hansen CBS 5926), Hansen CBS 5926, Levure de Boulangerie (Hansen CBS 5926), Probiotic, Probiotique, Saccharomyces, Saccharomyces boulardii, Saccharomyces Cerevisiae, S. Boulardii.


To learn more about how this article was written, please see the Natural Medicines Comprehensive Database methodology.


  1. Feizizadeh S, Salehi-Abargouei A, Akbari V. Efficacy and safety of Saccharomyces boulardii for acute diarrhea. Pediatrics. 2014;134:e176-191. View abstract.
  2. Szajewska H, Horvath A, Kolodziej M. Systematic review with meta-analysis: Saccharomyces boulardii supplementation and eradication of Helicobacter pylori infection. Aliment Pharmacol Ther. 2015;41:1237-1245. View abstract.
  3. Szajewska H, Kolodziej M. Systematic review with meta-analysis: Saccharomyces boulardii in the prevention of antibiotic -associated diarrhoea. Aliment Pharmacol Ther. 2015;42:793-801. View abstract.
  4. Ellouze O, Berthoud V, Mervant M, Parthiot JP, Girard C. Septic shock due to Sacccaromyces boulardii. Med Mal Infect. 2016;46:104-105. View abstract.
  5. Bafutto M, et al. Treatment of diarrhea-predominant irritable bowel syndrome with mesalamine and/or Saccharomyces boulardii. Arq Gastroenterol. 2013;50:304-309. View abstract.
  6. Bourreille A, et al. Saccharomyces boulardii does not prevent relapse of Crohn's disease. Clin Gastroenterol Hepatol. 2013;11:982-987.
  7. Serce O, Gursoy T, Ovali F, Karatekin G. Effects of Saccaromyces boulardii on neonatal hyperbilirubinemia: a randomized controlled trial. Am J Perinatol. 2015;30:137-142. View abstract.
  8. Elmer GW, Moyer KA, Vega R, and et al. Evaluation of Saccharomyces boulardii for patients with HIV-related chronic diarrhoea and in healthy volunteers receiving antifungals. Microecology Ther 1995;25:23-31.
  9. Potts L, Lewis SJ, and Barry R. Randomised double blind placebo controlled study of the ability of Saccharomyces boulardii to prevent antibiotic related diarrhoea [abstract]. Gut 1996;38 (suppl 1):A61.
  10. Bleichner G and Blehaut H. Saccharomyces boulardii prevents diarrhea in critically ill tube-fed patients. A multicenter, randomized, double-blind placebo-controlled trial [abstract]. Clin Nutr 1994;13 Suppl 1:10.
  11. Maupas JL, Champemont P, and Delforge M. [Treatment of irritable bowel syndrome with Saccharomyces boulardii - a double-blind, placebo controlled study]. Médicine et Chirurgie Digestives 1983;12:77-79.
  12. Saint-Marc T, Blehaut H, Musial C, and et al. [AIDS-related diarrhea: a double-blind trial of Saccharomyces boulardii]. Semaine Des Hopitaux 1995;71(23-24):735-741.
  13. McFarland LV, Surawicz C, Greenberg R, and et al. Saccharomyces boulardii and high dose vancomycin treats recurrent Clostridium difficile disease [abstract]. Am J Gastroenterol 1998;93:1694.
  14. Chouraqui JP, Dietsch J, Musial C, and et al. Saccharomyces boulardii (SB) in the management of toddler diarrhea: a double-blind-placebo controlled study [abstract]. J Pediatr Gastroenterol Nutr 1995;20:463.
  15. Cetina-Sauri G and Basto GS. Evaluacion terapeutica de Saccharomyces boulardii en ninos con diarrea aguda. Tribuna Med 1989;56:111-115.
  16. Adam J, Barret C, Barret-Bellet A, and et al. Essais cliniques controles en double insu de l'Ultra-Levure Lyophilisee. Etude multicentrique par 25 medecins de 388 cas. Gaz Med Fr 1977;84:2072-2078.
  17. McFarland LV, SurawiczCM, Elmer GW, and et al. Multivariate analysis of the clinical efficacy of a biotherapeutic agent, Saccharomyces boulardii for the prevention of antibiotic-associated diarrhea [abstract]. Am J Epidemiol 1993;138:649.
  18. Saint-Marc T, Rossello-Prats L, and Touraine JL. [Effectiveness of Saccharomyces boulardii in the management of AIDS diarrhea]. Ann Med Interne (Paris) 1991;142:64-65.
  19. Kirchhelle, A., Fruhwein, N., and Toburen, D. [Treatment of persistent diarrhea with S. boulardii in returning travelers. Results of a prospective study]. Fortschr Med 4-20-1996;114:136-140. View abstract.
  20. Born, P., Lersch, C., Zimmerhackl, B., and Classen, M. [The Saccharomyces boulardii therapy of HIV-associated diarrhea]. Dtsch Med Wochenschr 5-21-1993;118:765. View abstract.
  21. Kollaritsch, H., Holst, H., Grobara, P., and Wiedermann, G. [Prevention of traveler's diarrhea with Saccharomyces boulardii. Results of a placebo controlled double-blind study]. Fortschr.Med 3-30-1993;111:152-156. View abstract.
  22. Tempe, J. D., Steidel, A. L., Blehaut, H., Hasselmann, M., Lutun, P., and Maurier, F. [Prevention of diarrhea administering Saccharomyces boulardii during continuous enteral feeding]. Sem.Hop. 5-5-1983;59:1409-1412. View abstract.
  23. Chapoy, P. [Treatment of acute infantile diarrhea: controlled trial of Saccharomyces boulardii]. Ann Pediatr.(Paris) 1985;32:561-563. View abstract.
  24. Kimmey, M. B., Elmer, G. W., Surawicz, C. M., and McFarland, L. V. Prevention of further recurrences of Clostridium difficile colitis with Saccharomyces boulardii. Dig.Dis Sci 1990;35:897-901. View abstract.
  25. Saint-Marc, T., Rossello-Prats, L., and Touraine, J. L. [Efficacy of Saccharomyces boulardii in the treatment of diarrhea in AIDS]. Ann Med Interne (Paris) 1991;142:64-65. View abstract.
  26. Duman, D. G., Bor, S., Ozutemiz, O., Sahin, T., Oguz, D., Istan, F., Vural, T., Sandkci, M., Isksal, F., Simsek, I., Soyturk, M., Arslan, S., Sivri, B., Soykan, I., Temizkan, A., Bessk, F., Kaymakoglu, S., and Kalayc, C. Efficacy and safety of Saccharomyces boulardii in prevention of antibiotic-associated diarrhoea due to Helicobacterpylori eradication. Eur J Gastroenterol.Hepatol. 2005;17:1357-1361. View abstract.
  27. Surawicz, C. M. Treatment of recurrent Clostridium difficile-associated disease. Nat Clin Pract.Gastroenterol.Hepatol. 2004;1:32-38. View abstract.
  28. Kurugol, Z. and Koturoglu, G. Effects of Saccharomyces boulardii in children with acute diarrhoea. Acta Paediatr. 2005;94:44-47. View abstract.
  29. Kotowska, M., Albrecht, P., and Szajewska, H. Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea in children: a randomized double-blind placebo-controlled trial. Aliment.Pharmacol.Ther. 3-1-2005;21:583-590. View abstract.
  30. Cherifi, S., Robberecht, J., and Miendje, Y. Saccharomyces cerevisiae fungemia in an elderly patient with Clostridium difficile colitis. Acta Clin Belg. 2004;59:223-224. View abstract.
  31. Erdeve, O., Tiras, U., and Dallar, Y. The probiotic effect of Saccharomyces boulardii in a pediatric age group. J Trop.Pediatr. 2004;50:234-236. View abstract.
  32. Costalos, C., Skouteri, V., Gounaris, A., Sevastiadou, S., Triandafilidou, A., Ekonomidou, C., Kontaxaki, F., and Petrochilou, V. Enteral feeding of premature infants with Saccharomyces boulardii. Early Hum.Dev. 2003;74:89-96. View abstract.
  33. Gaon, D., Garcia, H., Winter, L., Rodriguez, N., Quintas, R., Gonzalez, S. N., and Oliver, G. Effect of Lactobacillus strains and Saccharomyces boulardii on persistent diarrhea in children. Medicina (B Aires) 2003;63:293-298. View abstract.
  34. Mansour-Ghanaei, F., Dehbashi, N., Yazdanparast, K., and Shafaghi, A. Efficacy of saccharomyces boulardii with antibiotics in acute amoebiasis. World J Gastroenterol. 2003;9:1832-1833. View abstract.
  35. Riquelme, A. J., Calvo, M. A., Guzman, A. M., Depix, M. S., Garcia, P., Perez, C., Arrese, M., and Labarca, J. A. Saccharomyces cerevisiae fungemia after Saccharomyces boulardii treatment in immunocompromised patients. J Clin.Gastroenterol. 2003;36:41-43. View abstract.
  36. Cremonini, F., Di Caro, S., Santarelli, L., Gabrielli, M., Candelli, M., Nista, E. C., Lupascu, A., Gasbarrini, G., and Gasbarrini, A. Probiotics in antibiotic-associated diarrhoea. Dig.Liver Dis. 2002;34 Suppl 2:S78-S80. View abstract.
  37. Lherm, T., Monet, C., Nougiere, B., Soulier, M., Larbi, D., Le Gall, C., Caen, D., and Malbrunot, C. Seven cases of fungemia with Saccharomyces boulardii in critically ill patients. Intensive Care Med 2002;28:797-801. View abstract.
  38. Tasteyre, A., Barc, M. C., Karjalainen, T., Bourlioux, P., and Collignon, A. Inhibition of in vitro cell adherence of Clostridium difficile by Saccharomyces boulardii. Microb.Pathog. 2002;32:219-225. View abstract.
  39. Shanahan, F. Probiotics in inflamatory bowel disease. Gut 2001;48:609. View abstract.
  40. Surawicz, C. M., McFarland, L. V., Greenberg, R. N., Rubin, M., Fekety, R., Mulligan, M. E., Garcia, R. J., Brandmarker, S., Bowen, K., Borjal, D., and Elmer, G. W. The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Clin.Infect.Dis. 2000;31:1012-1017. View abstract.
  41. Johnston BC, Ma SSY, Goldenberg JZ, et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea. Ann Intern Med 2012;157:878-8. View abstract.
  42. Munoz P, Bouza E, Cuenca-Estrella M, et al. Saccharomyces cerevisiae fungemia: an emerging infectious disease. Clin Infect Dis 2005;40:1625-34. View abstract.
  43. Szajewska H, Mrukowicz J. Meta-analysis: non-pathogenic yeast Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea. Aliment Pharmacol Ther 2005;22:365-72. View abstract.
  44. Can M, Besirbellioglu BA, Avci IY, et al. Prophylactic Saccharomyces boulardii in the prevention of antibiotic-associated diarrhea: A prospective study. Med Sci Monit 2006;12:PI19-22. View abstract.
  45. Guslandi M, Giollo P, Testoni PA. A pilot trial of Saccharomyces boulardii in ulcerative colitis. Eur J Gastroenterol Hepatol 2003;15:697-8. View abstract.
  46. Guslandi M, Mezzi G, Sorghi M, Testoni PA. Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig Dis Sci 2000;45:1462-4. View abstract.
  47. McFarland LV. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Am J Gastroenterol 2006;101:812-22. View abstract.
  48. Marteau P, Seksik P. Tolerance of probiotics and prebiotics. J Clin Gastroenterol 2004;38:S67-9. View abstract.
  49. Borriello SP, Hammes WP, Holzapfel W, et al. Safety of probiotics that contain lactobacilli or bifidobacteria. Clin Infect Dis 2003;36:775-80. View abstract.
  50. Cremonini F, Di Caro S, Covino M, et al. Effect of different probiotic preparations on anti-helicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo-controlled study. Am J Gastroenterol 2002;97:2744-9. View abstract.
  51. D'Souza AL, Rajkumar C, Cooke J, Bulpitt CJ. Probiotics in prevention of antibiotic associated diarrhoea: meta-analysis. BMJ 2002;324:1361. View abstract.
  52. Muller J, Remus N, Harms KH. Mycoserological study of the treatment of paediatric cystic fibrosis patients with Saccharomyces boulardii (Saccharomyces cerevisiae Hansen CBS 5926). Mycoses 1995;38:119-23. View abstract.
  53. Plein K, Hotz J. Therapeutic effects of Saccharomyces boulardii on mild residual symptoms in a stable phase of Crohn's disease with special respect to chronic diarrhea - a pilot study. Z Gastroenterol 1993;31:129-34. View abstract.
  54. Hennequin C, Thierry A, Richard GF, et al. Microsatellite typing as a new tool for identification of Saccharomyces cerevisiae strains. J Clin Microbiol 2001;39:551-9. View abstract.
  55. Cesaro S, Chinello P, Rossi L, Zanesco L. Saccharomyces cerevisiae fungemia in a neutropenic patient treated with Saccharomyces boulardii. Support Care Cancer 2000;8:504-5. View abstract.
  56. Weber G, Adamczyk A, Freytag S. [Treatment of acne with a yeast preparation]. Fortschr Med 1989;107:563-6. View abstract.
  57. Lewis SJ, Freedman AR. Review article: the use of biotherapeutic agents in the prevention and treatment of gastrointestinal disease. Aliment Pharmacol Ther 1998;12:807-22. View abstract.
  58. Krammer M, Karbach U. Antidiarrheal action of the yeast Saccharomyces boulardii in the rat small and large intestine by stimulating chloride absorption. Z Gastroenterol 1993;31:73-7.
  59. Czerucka D, Roux I, Rampal P. Saccharomyces boulardii inhibits secretagogue-mediated adenosine 3',5'-cyclic monophosphate induction in intestinal cells. Gastroenterol 1994;106:65-72. View abstract.
  60. Elmer GW, McFarland LV, Surawicz CM, et al. Behaviour of Saccharomyces boulardii in recurrent Clostridium difficile disease patients. Aliment Pharmacol Ther 1999;13:1663-8. View abstract.
  61. Hennequin C, Kauffmann-Lacroix C, Jobert A, et al. Possible role of catheters in Saccharomyces boulardii fungemia. Eur J Clin Microbiol Infect Dis 2000;19:16-20. View abstract.
  62. Fredenucci I, Chomarat M, Boucaud C, et al. Saccharomyces boulardii fungemia in a patient receiving ultra-levure therapy. Clin Infect Dis 1998;27:222-3. View abstract.
  63. Pletinex M, Legein J, Vandenplas Y. Fungemia with Saccharomyces boulardii in a 1-year-old girl with protracted diarrhea. J Pediatr Gastroenterol Nutr 1995;21:113-5. View abstract.
  64. Buts JP, Corthier G, Delmee M. Saccharomyces boulardii for Clostridium difficile-associated enteropathies in infants. J Pediatr Gastroenterol Nutr 1993;16:419-25. View abstract.
  65. Surawicz CM, Elmer GW, Speelman P, et al. Prevention of antibiotic-associated diarrhea by Saccharomyces boulardii: a prospective study. Gastroenterology 1989;96:981-8. View abstract.
  66. Surawicz CM, McFarland LV, Elmer G, et al. Treatment of recurrent clostridium difficile colitis with vancomycin and Saccharomyces boulardii. Am J Gastroenterol 1989;84:1285-7. View abstract.
  67. McFarland LV, Surawicz CM, Greenberg RN, et al. Prevention of beta-lactam associated diarrhea by Saccharomyces boulardii compared with placebo. Am J Gastroenterol 1995;90:439-48. View abstract.
  68. McFarland LV, Surawicz CM, Greenberg RN, et al. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA 1994;271:1913-8. View abstract.
  69. Elmer GW, McFarland LV. Comment on the lack of therapeutic effect of Saccharomyces boulardii in the prevention of antibiotic-related diarrhea in elderly patients. J Infect 1998;37:307-8. View abstract.
  70. Lewis SJ, Potts LF, Barry RE. The lack of therapeutic effect of Saccharomyces boulardii in the prevention of antibiotic-related diarrhea in elderly patients. J Infect 1998;36:171-4. View abstract.
  71. Bleichner G, Blehaut H, Mentec H, et al. Saccharomyces boulardii prevents diarrhea in critically ill tube-fed patients. Intensive Care Med 1997;23:517-23. View abstract.
  72. Castagliuolo I, Riegler MF, Valenick L, et al. Saccharomyces boulardii protease inhibits the effects of clostridium difficile toxins A and B in human colonic mucosa. Infection and Immun 1999;67:302-7. View abstract.
  73. Saavedra J. Probiotics and infectious diarrhea. Am J Gastroenterol 2000;95:S16-8. View abstract.
  74. McFarland LV. Saccharomyces boulardii is not Saccharomyces cerevisiae. Clin Infect Dis 1996;22:200-1. View abstract.
  75. McCullough MJ, Clemons KV, McCusker JH, Stevens DA. Species identification and virulence attributes of Saccharomyces boulardii (nom. inval.). J Clin Microbiol 1998;36:2613-7. View abstract.
  76. Niault M, Thomas F, Prost J, et al. Fungemia due to Saccharomyces species in a patient treated with enteral Saccharomyces boulardii. Clin Infect Dis 1999;28:930. View abstract.
  77. Bassetti S, Frei R, Zimmerli W. Fungemia with Saccharomyces cerevisiae after treatment with Saccharomyces boulardii. Am J Med 1998;105:71-2. View abstract.
  78. Scarpignato C, Rampal P. Prevention and treatment of traveler's diarrhea: A clinical pharmacological approach. Chemotherapy 1995;41:48-81. View abstract.
Last reviewed - 12/01/2017